Key terms
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALPN news
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
8:36am ET
Vera Therapeutics price target raised to $34 from $21 at Wedbush
Mar 21
2:16am ET
Buy Rating Affirmed for Alpine Immune Sciences Amid Positive Povetacicept Trials and Strong Clinical Outlook
Mar 21
2:02am ET
Alpine Immune Sciences’ Growth at Risk: Navigating FDA and SEC Disruptions Amidst Political and Health Uncertainties
Mar 20
11:06am ET
Biotech Alert: Searches spiking for these stocks today
Mar 19
8:50am ET
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
Mar 19
8:07am ET
Alpine Immune Sciences price target raised to $47 from $30 at Morgan Stanley
Mar 19
7:38am ET
Alpine Immune Sciences price target raised to $44 from $33 at Oppenheimer
Mar 19
6:50am ET
Analysts’ Top Healthcare Picks: Biofrontera (BFRI), Alpine Immune Sciences (ALPN)
Mar 19
6:17am ET
Alpine Immune Sciences: A Strong Buy on Robust Clinical Progress and Financial Stability
Mar 19
6:08am ET
Alpine Immune Sciences price target raised to $50 from $32 at H.C. Wainwright
Mar 18
6:55pm ET
Buy Rating Affirmed for Alpine Immune Sciences Amidst Promising Clinical Trials and Forthcoming Data
Mar 18
4:34pm ET
Alpine Immune Sciences Highlights Key Communication Channels
Mar 18
4:11pm ET
Alpine Immune Sciences says cash sufficient to fund operations into 2026
Mar 18
4:11pm ET
Alpine Immune Sciences reports FY23 EPS (64c), consensus ($1.10)
Mar 18
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 18, 2024
Mar 12
9:16am ET
Alpine Immune Sciences price target raised to $41 from $29 at RBC Capital
Mar 12
6:45am ET
RBC Capital Reaffirms Their Buy Rating on Alpine Immune Sciences (ALPN)
Feb 16
5:06pm ET
Alpine Immune Sciences assumed with an Outperform at Oppenheimer
Feb 14
7:13pm ET
Wolfe starts Alpine at Outperform, says bullish on de-risked mechanism
Feb 14
4:14pm ET
Alpine Immune Sciences initiated with an Outperform at Wolfe Research
Feb 08
4:36am ET
Alpine Immune Sciences Expands Investor Base with Warrant Exercises
Jan 29
11:20pm ET
Analysts Offer Insights on Healthcare Companies: Alpine Immune Sciences (ALPN) and ACADIA Pharmaceuticals (ACAD)
Jan 26
8:36am ET
Alpine Immune Sciences price target raised to $33 from $30 at Oppenheimer
Jan 26
8:32am ET
Analysts’ Top Healthcare Picks: Siemens Healthineers AG (SEMHF), Dianthus Therapeutics (DNTH)
Jan 26
8:31am ET
Alpine Immune Sciences price target raised to $35 from $26 at Wedbush
Jan 26
8:03am ET
Analysts Are Bullish on Top Healthcare Stocks: Alpine Immune Sciences (ALPN), Exelixis (EXEL)
Jan 09
7:00am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Dec 25
5:38am ET
3 Best Stocks to Buy Now, 12/25/2023, According to Top Analysts
Dec 25
12:45am ET
Buy Rating Affirmed for Alpine Immune Sciences with Focus on Povetacicept as Key Driver
No recent news articles are available for ALPN
No recent press releases are available for ALPN
ALPN Financials
Key terms
Ad Feedback
ALPN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALPN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range